Claims for Patent: 10,435,452

Summary for Patent: 10,435,452

Title:	Cadherin 26 (CDH26)-Fc fusion proteins and methods of use thereof to treat inflammatory conditions
Abstract:	The invention provides (CDH26)-based therapeutic agent, compositions comprising same, and methods of treating inflammatory conditions using same.
Inventor(s):	Rothenberg; Marc E. (Cincinnati, OH), Caldwell; Julie (Cincinnati, OH)
Assignee:	CHILDREN\'S HOSPITAL MEDICAL CENTER (Cincinnati, OH)
Application Number:	15/577,502
Patent Claims:	1. A fusion protein comprising two polypeptide segments, 1 and 2, segment 1 comprising or consisting of an extracellular region of the human cadherin 26 (CDH26) protein defined by EC1 (SEQ ID NO: 2), or fragment thereof, said fragment consisting of from 20-50 contiguous amino acids of SEQ ID NO: 2, and segment 2 comprising or consisting of a heavy chain constant region (Fc) of a human immunoglobulin (Ig) molecule. 2. The fusion protein of claim 1, wherein segment 1 comprises one or more additional extracellular cadherin repeat domains (EC) of human CDH26 selected from the group consisting of EC2, EC3, EC4, and EC5. 3. The fusion protein of claim 2, wherein segment 1 comprises or consists of SEQ ID NO: 10. 4. The fusion protein of claim 2, wherein segment 1 further comprises EC2 (SEQ ID NO: 3), or a contiguous amino acid fragment thereof, said fragment consisting of from 20 to 50 contiguous amino acids of SEQ ID NO: 3. 5. The fusion protein of claim 2, wherein segment 1 further comprises EC50 (SEQ ID NO: 4), or a contiguous amino acid fragment thereof, said fragment consisting of from 20 to 50 contiguous amino acids of SEQ ID NO: 4. 6. The fusion protein of claim 2, wherein segment 1 comprises or consists of EC4 (SEQ ID NO: 5), or a contiguous amino acid fragment thereof, said fragment consisting of from 20 to 50 contiguous amino acids of SEQ ID NO: 5. 7. The fusion protein of claim 2, wherein segment 1 comprises or consists of EC5 (SEQ ID NO: 6), or a contiguous amino acid fragment thereof, said fragment consisting of from 20 to 50 contiguous amino acids of SEQ ID NO: 6. 8. The fusion protein of claim 1, wherein the Ig molecule is selected from the group consisting of IgG, IgE, IgM, IgD, IgA and IgY. 9. The fusion protein of claim 8, wherein the Ig molecule is an IgG or IgA molecule. 10. The fusion protein of claim 9, wherein the IgG or IgA molecule is selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. 11. The fusion protein of claim 10, wherein the Ig molecule is selected from the group consisting of IgG1, IgG4, IgA1 and IgA2. 12. The fusion protein of claim 11, wherein the Ig molecule is IgG1. 13. The fusion protein of claim 12, wherein segment 2 comprises or consists of SEQ ID NO: 7. 14. The fusion protein of claim 1, further comprising a signal sequence. 15. The fusion protein of claim 14, wherein the signal sequence is selected from a signal peptide of any one of interleukin-2, CD5, immunoglobulin kappa light chain, trypsinogen, serum albumin, and prolactin, and functional fragments thereof. 16. The fusion protein of claim 1, further comprising a linker sequence between segments 1 and 2. 17. The fusion protein of claim 16, wherein the linker sequence comprises or consists of from 2 to 10 amino acids. 18. The fusion protein of claim 1, wherein the fusion protein comprises or consists of SEQ ID NO: 8. 19. A modified fusion protein according to claim 1, wherein the amino acid sequence of the modified fusion protein is from 90 to 99% identical to the unmodified sequence. 20. A modified fusion protein according to claim 1, wherein the sequence of segment 2 is modified to improve the aqueous solubility, stability, avidity, and/or pharmacokinetics of the fusion protein. 21. The modified fusion protein of claim 20, wherein the sequence of segment 2 is modified to reduce complement binding or antibody dependent cytotoxicity. 22. A composition or pharmaceutical composition comprising the fusion protein of claim 1. 23. The composition or pharmaceutical composition of claim 22, further comprising a pharmaceutically acceptable carrier or excipient. 24. The composition or pharmaceutical composition of claim 23, which is formulated for topical administration. 25. The composition or pharmaceutical composition of claim 23, further comprising at least one additional active agent selected from an IL-13 inhibitor, a non-steroidal anti-inflammatory drug (NSAID), a cytokine inhibitor, a bronchodilator, omalizumab, mepolizumab, or reslizumab, an immunosuppressive agent, 6 mercaptopurine, or a steroid. 26. A method for treating an inflammatory disease, disorder, or condition in a subject in need thereof, the method comprising administering to the subject an amount of the pharmaceutical composition of claim 23. 27. A fusion protein consisting of an extracellular region of human CDH26 and an Fc region of an Ig molecule, the extracellular region of CDH26 comprising an extracellular cadherin repeat domain 1 of SEQ ID NO: 2 (EC1), or a fragment thereof, said fragment consisting of from 20-50 contiguous amino acids of SEQ ID NO: 2. 28. The fusion protein of claim 27, wherein the extracellular region further comprises one or more additional extracellular cadherin repeat domains (EC) of human CDH26 selected from the group consisting of EC2, EC3, EC4, and EC5, or a fragment thereof consisting of from 20 to 50 contiguous amino acids. 29. The fusion protein of claim 28, wherein the extracellular region comprises or consists of SEQ ID NO: 10. 30. The fusion protein of claim 29, wherein the Fc region comprises or consists of SEQ ID NO: 7. 31. The fusion protein of claim 27, wherein the sequence of EC1 is modified to alter integrin binding by substituting one or more amino acid residues corresponding to N85, D98, E99, E102 and E138 of SEQ ID NO:11. 32. The fusion protein of claim 27, wherein the sequence of EC1 is modified to alter homodimer formation by substituting the amino acid residue corresponding to W56 of CDH26 (SEQ ID NO:11). 33. The fusion protein of claim 28, wherein the sequence is modified to alter glycosylation of the fusion protein by substituting one or more amino acids residues corresponding to N81, N85, N171, N177 and N462 of CDH26 (SEQ ID NO:11).

Details for Patent 10,435,452

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	06/20/2003		2035-05-29
Genentech, Inc.	XOLAIR	omalizumab	Injection	103976	09/28/2018		2035-05-29
Glaxosmithkline Llc	NUCALA	mepolizumab	For Injection	125526	11/04/2015		2035-05-29
Glaxosmithkline Llc	NUCALA	mepolizumab	Injection	125526	06/06/2019		2035-05-29